News

CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Manage ...
Sailfish Royalty Corp.: Sailfish Royalty Declares Q2 2025 Dividend
Sailfish Royalty Corp. (TSXV: FISH) (OTCQX: SROYF) (the "Company" or "Sailfish") is pleased to announce that its Board of Directors has ...
BK Technologies Corporation: BK Technologies Announces First Quarter 2025 Results
Revenue growth to $19.1 million; Achieves gross margin of 47.0%1Q25 GAAP diluted EPS of $0.55 compared with $0.19 in 1Q241Q25 non-GAAP diluted adjusted EPS1 of $0.68 compared with $0.30 in 1Q24Reitera ...
Börsenplatz Zürich: Adecco - mit KI und Flexibilität in die Zukunft
Die Geschäfte könnten bei Adecco besser laufen. Im ersten Quartal 2025 ging der Umsatz zurück. Sorgenkind ist die Technologieberater-Sparte Akkodis. Für die Zukunft sieht sich Adecco trotzdem gut aufg ...